Resumen
INTRODUCCIÓN:El desarrollo de anticuerpos monoclonales (mAbs) contra el péptido relacionado con el gen de la calcitonina (CGRP) ha determinado una nueva era terapéutica en la profilaxis de migraña, demostrando su efectividad en pacientes con migraña episódica (ME) y migraña crónica (MC), con respuesta desde pacientes naïve hasta refractarios a múltiples medicamentos. La disminución del 50% de los ataques de migraña al mes (DMM) durante los primeros 3 meses de uso es el desenlace aproximado en el 50% de los pacientes que reciben esta terapia.
OBJETIVO:Este consenso de la Asociación Colombiana de Neurología (ACN) tiene el objetivo de guiar la selección y uso racional de los mAbs antiCGRP en pacientes con ME y MC.
MATERIALES Y MÉTODOS:El comité de cefalea de la ACN mediante la aplicación de la metodología Delphi y discusiones en reuniones posteriores desarrolló un documento en formato de consenso soportado en literatura y recomendaciones de expertos.
RESULTADOS:Se obtuvieron respuestas de 14 expertos en cefalea sobre moléculas utilizadas en profilaxis de migraña, analizando su aplicabilidad en situaciones clínicas frecuentes.
DISCUSIÓN:Los mAbs antiCGRP han demostrado efectividad con adecuado soporte fisiopatológico, considerando que son moléculas de alto precio en una enfermedad de alta prevalencia, existe la necesidad de guíar la selección del paciente que mejor puede beneficiarse de su administración
CONCLUSIONES:Los mAbs antiCGRP están recomendados en pacientes con ME y MC que presentan falla terapéutica a otras moléculas profilácticas.
Citas
Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343-9. https://doi.org/10.1212/01.wnl.0000252808.97649.21.
Yeh WZ, Blizzard L, Taylor BV. What is the actual prevalence of migraine? Brain Behav. 2018;8:e00950. https://doi.org/10.1002/brb3.950.
Pradilla G, Vesga BE, Díaz LA, Pinto NX, Sanabria CL, Baldovino BP, et al. Estudio neuroepidemiológico en la comunidad urbana de Piedecuesta Santander. Acta Med Colomb. 2002;27:407-20.
Morillo LE, Alarcon F, Aranaga N, Aulet S, Chapman E, Conterno L, et al. Prevalence of migraine in Latin America. Headache J Head Face Pain. 2005;45:106-17. https://doi.org/10.1111/j.1526-4610.2005.05024.x.
Rueda-Sánchez M, Díaz-Martínez L. Prevalence and associated factors for episodic and chronic daily headache in the Colombian population. Cephalalgia. 2008;28:216-25. https://doi.org/10.1111/j.1468-2982.2007.01499.x.
Natoli J, Manack A, Dean B, Butler Q, Turkel C, Stovner L, et al. Global prevalence of chronic migraine: a systematic review Cephalalgia. 2009;30:599-609. https://doi.org/10.1111/j.1468-2982.2009.01941.x.
Rueda-Sánchez M. Cefalea por uso excesivo de analgésicos en Bucaramanga, Colombia: Prevalencia y factores asociados. Acta Neurol Colomb. 2013;29:20-6.
Schwedt TJ. Chronic migraine. Bmj Br Medical J. 2014;348:g1416. https://doi.org/10.1136/bmj.g1416.
Torres-Ferrús M, Ursitti F, Alpuente A, Brunello F, Chiappino D, et al. From transformation to chronification of migraine: pathophysiological and clinical aspects. J Headache Pain. 2020;21:42. https://doi.org/10.1186/s10194-020-01111-8.
Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2014;35:478-88. https://doi.org/10.1177/0333102414547138.
Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, et al. EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. Eur J Neurol. 2009;16:968-81. https://doi.org/10.1111/j.1468-1331.2009.02748.x.
Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E, et al. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337-45. https://doi.org/10.1212/wnl.0b013e3182535d20.
Muñoz-Cerón JF, Rueda-Sánchez M, Pradilla-Vesga OE, Volcy M, Hernández N, Ramírez SF, et al. Guía de la Asociación Colombiana de Neurología para el tratamiento preventivo de la migraña crónica, cefalea tipo tensión crónica, hemicránea continua y cefalea diaria persistente de novo. Acta Neurológica Colombiana. 2020;36:131-49. https://doi.org/10.22379/24224022299.
Amara SG, David DN, Rosenfeld MG, Roos BA, Evans RM. Characterization of rat calcitonin mRNA. Proc Natl Acad Sci. 1980;77:4444-8. https://doi.org/10.1073/pnas.77.8.4444.
Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28:183-7. https://doi.org/10.1002/ana.410280213.
Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988;23:193-6. https://doi.org/10.1002/ana.410230214.
Buss NA, Henderson SJ, McFarlane M, Shenton JM, Haan L de. Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol. 2012;12:615-22. https://doi.org/10.1016/j.coph.2012.08.001.
Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas D-D, et al. European Headache Federation guideline on the use of monoclonal antibodies acting on the calci-tonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20:6. https://doi.org/10.1186/s10194-018-0955-y.
Society A. The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache J Head Face Pain. 2019;59:1-18. https://doi.org/10.1111/head.13456.
Doctorovich ED, Bertuzzi FM, Goicochea MT, Miranda S, Figuerola M de L, Schubaroff PA, et al. Consenso sobre el uso de anticuerpos monoclonales en la migraña en Argentina. Revista De Neurología. 2020;70:149. https://doi.org/10.33588/rn.7004.2019399.
Santos-Lasaosa S, Belvís R, Cuadrado ML, Díaz-Insa S, Gago-Veiga A, Guerrero-Peral AL, et al. CGRP en migraña: de la fisiopatología a la terapéutica. Neurología. 2019. https://doi.org/10.1016/j.nrl.2019.03.013.
Tassorelli C, Diener H-C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia. 2018;38:815-32. https://doi.org/10.1177/0333102418758283.
Vo P, Wen S, Martel M-JJ, Mitsikostas D, Reuter U, Klatt J. Benefit-risk assessment of erenumab and current migraine prophylactic treatments using the likelihood of being helped or harmed. Cephalalgia. 2018:333102418801579. https://doi.org/10.1177/0333102418801579.
Sussman M, Benner J, Neumann P, Menzin J. Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: Results from the US societal and payer perspectives. Cephalalgia. 2018;38:1644-1657. https://doi.org/10.1177/0333102418796842.
Mahon R, Lang A, Vo P, Huels J, Cooney P, Danyliv A, et al. Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden. Pharmacoeconomics. 2021;39:357-72. https://doi.org/10.1007/s40273-020-00996-2.
Huang I-H, Wu P-C, Lin E-Y, Chen C-Y, Kang Y-N. Effects of Anti-Calcitonin Gene-Related Peptide for Migraines: A Systematic Review with Meta-Analysis of Randomized Clinical Trials. Int J Mol Sci. 2019;20:3527. https://doi.org/10.3390/ijms20143527.
Lattanzi S, Brigo F, Trinka E, Vernieri F, Corradetti T, Dobran M, et al. Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety. Drugs. 2019;79. https://doi.org/10.1007/s40265-019-01069-1.
Xu D, Chen D, Zhu L, Tan G, Wang H, Zhang Y, et al. Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials. Cephalalgia. 2018;39:1164-79. https://doi.org/10.1177/0333102419829007.
Hou M, Xing H, Cai Y, Li B, Wang X, Li P, et al. The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis. J Headache Pain. 2017;18:42. https://doi.org/10.1186/s10194-017-0750-1.
Zhu Y, Liu Y, Zhao J, Han Q, Liu L, Shen X. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis. Neurol Sci. 2018;39. https://doi.org/10.1007/s10072-018-3547-3.
Szperka CL, VanderPluym J, Orr SL, Oakley CB, Qubty W, Patniyot I, et al. Recommendations on the Use of Anti-CGRP Monoclonal Antibodies in Children and Adolescents. Headache J Head Face Pain. 2018;58:1658-69. https://doi.org/10.1111/head.13414.
Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. Jama. 2018;319:1999-2008. https://doi.org/10.1001/jama.2018.4853.
Goadsby PJ, Reuter U, Hallstróm Y, Broessner G, Bonner JH, Zhang F, et al. A Controlled Trial of Erenumab for Episodic Migraine. New Engl J Med. 2017;377:2123-32. https://doi.org/10.1056/nejmoa1705848.
Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim B-K, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38:1442-54. https://doi.org/10.1177/0333102418779543.
Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J, et al. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40:241-54. https://doi.org/10.1177/0333102420905132.
Dodick DW, Lipton RB, Silberstein S, Goadsby PJ, Biondi D, Hirman J, et al. Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. Cephalalgia. 2019;39:1075-85. https://doi.org/10.1177/0333102419858355.
Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019;394:1030-40. https://doi.org/10.1016/s0140-6736(19)31946-4.
Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91:10.1212/WNL.0000000000006640. https://doi.org/10.1212/wnl.0000000000006640.
Tepper S, Ashina M, Reuter U, Brandes JL, Dolezil D, Silberstein S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16:425-34. https://doi.org/10.1016/s1474-4422(17)30083-2.
Diener H, Bussone G, Oene JV, Lahaye M, Schwalen S, Goadsby P. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814-23. https://doi.org/10.1111/j.1468-2982.2007.01326.x.
Pavlovic JM, Paemeleire K, Gôbel H, Bonner J, Rapoport A, Kagan R, et al. Efficacy and safety of erenumab in women with a history of menstrual migraine. J Headache Pain. 2020;21:95. https://doi.org/10.1186/s10194-020-01167-6.
Martelletti P, Katsarava Z, Lampl C, Magis D, Bendtsen L, Negro A, et al. Refractory chronic migraine: a Consensus Statement on clinical definition from the European Headache Federation. J Headache Pain. 2014;15:47. https://doi.org/10.1186/1129-2377-15-47.
Sacco S, Braschinsky M, Ducros A, Lampl C, Little P, Brink AM van den, et al. European Headache Federation consensus on the definition of resistant and refractory migraine. J Headache Pain. 2020;21:76. https://doi.org/10.1186/s10194-020-01130-5.
Schwedt TJ. Preventive Therapy of Migraine. Continuum Lifelong Learn Neurology. 2018;24:1052-65. https://doi.org/10.1212/con.0000000000000635.
Silberstein SD. Preventive Migraine Treatment. Neurol Clin. 2009;27:429-43. https://doi.org/10.1016/j.ncl.2008.11.007.
Robblee J, Starling AJ. SEEDS for success: Lifestyle management in migraine. Clev Clin J Med. 2019;86:741-9. https://doi.org/10.3949/ccjm.86a.19009.
Ailani J, Burch RC, Robbins MS, Society the B of D of the AH. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache J Head. Face Pain 2021. https://doi.org/10.1111/head.14153.
Bendtsen L, Sacco S, Ashina M, Mitsikostas D, Ahmed F, Pozo-Rosich P, et al. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. J Headache Pain. 2018;19:91. https://doi.org/10.1186/s10194-018-0921-8.
Mulleners WM, Kim B-K, Láinez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S, et al. Safety and efficacy of galcan-ezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020;19:814-25. https://doi.org/10.1016/s1474-4422(20)30279-9.
Frampton JE. OnabotulinumtoxinA in Chronic Migraine: A Profile of Its Use. Cns Drugs. 2020;34:1287-98. https://doi.org/10.1007/s40263-020-00776-8.
Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program. Headache J Head Face Pain. 2010;50:921-36. https://doi.org/10.1111/j.1526-4610.2010.01678.x.
Aurora SK, Dodick DW, Diener H -C., DeGryse RE, Turkel CC, Lipton RB, et al. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program. Acta Neurol Scand. 2014;129:61-70. https://doi.org/10.1111/ane.12171.
Lu J, Zhang Q, Guo X, Liu W, Xu C, Hu X, et al. Calcitonin Gene-Related Peptide Monoclonal Antibody Versus Botulinum Toxin for the Preventive Treatment of Chronic Migraine: Evidence From Indirect Treatment Comparison. Front Pharmacol. 2021;12:631204. https://doi.org/10.3389/fphar.2021.631204.
Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804-14. https://doi.org/10.1177/0333102410364677.
Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Adams AM. Long-term study of the efficacy and safety of Ona-botulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19:13. https://doi.org/10.1186/s10194-018-0840-8.
Patricia P, Sonia S. Manual de Practica Clinica en Cefaleas. Recomendaciones diagnóstico- terapéuticas de la Sociedad Española de Neurología. 2020. Disponible en https://www.sen.es/pdf/2020/ManualCefaleas2020.pdf
Pellesi L, Do TP, Ashina H, Ashina M, Burstein R. Dual Therapy With Anti-CGRP Monoclonal Antibodies and Botu-linum Toxin for Migraine Prevention: Is There a Rationale? Headache J Head Face Pain. 2020;60:1056-65. https://doi.org/10.1111/head.13843.
Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392:2280-7. https://doi.org/10.1016/s0140-6736(18)32534-0.
Pías EM, Azorin DG, López JT, Sierra Á, Peral ÁLG. Migraña crónica con cefalea diaria. Revisión de la bibliografía. Revista De Neurología. 2021;72:133. https://doi.org/10.33588/rn.7204.2020583.
Cho S-J, Chu MK. Risk Factors of Chronic Daily Headache or Chronic Migraine. Curr Pain Headache R. 2014;19:465. https://doi.org/10.1007/s11916-014-0465-9.
Garzal I, Schwedt2 T. Diagnosis and Management of Chronic Daily Headache. Semin Neurol. 2010;30:154-66. https://doi.org/10.1055/s-0030-1249224.
Riesco N, Cernuda-Morollón E, Pascual J. Neuropeptides as a Marker for Chronic Headache. Curr Pain Headache R. 2017;21:18. https://doi.org/10.1007/s11916-017-0618-8.
Cernuda-Morollón E, Martinez-Camblor P, Ramón C, Larrosa D, Serrano-Pertierra E, Pascual J. CGRP and VIP Levels as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine. Headache J Head Face Pain. 2014;54:987-95. https://doi.org/10.1111/head.12372.
Dominguez C, Vieites-Prado A, Pérez-Mato M, Sobrino T, Rodríguez-Osorio X, López A, et al. CGRP and PTX3 as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine: An Observational Study. Headache J Head Face Pain. 2018;58:78-87. https://doi.org/10.1111/head.13211.
Cernuda-Morollón E, Ramón C, Martínez-Camblor P, Serrano-Pertierra E, Larrosa D, Pascual J. Onabotulinum-toxinA decreases interictal CGRP plasma levels in patients with chronic migraine. Pain. 2015;156:820-4. https://doi.org/10.1097/j.pain.0000000000000119.
Titus F, Lánez MJA. Abstracts. Cephalalgia. 1999;19:251-475. https://doi.org/10.1046/j.1468-2982.1999.019004251.x.
Martínez-Pías E, Guerrero ÁL, Sierra Á, Trigo J, García-Azorín D. Daily Headache in Chronic Migraine Is a Predictive Factor of Response in Patients Who Had Completed Three Sessions of OnabotulinumtoxinA. Toxins. 2021;13:432. https://doi.org/10.3390/toxins13060432.
Young WB, Lopez JI, Rothrock JF, Orejudos A, Adams AM, Lipton RB, et al. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study. J Headache Pain. 2019;20:12. https://doi.org/10.1186/s10194-018-0953-0.
Jackson JL, Kuriyama A, Hayashino Y Botulinum Toxin A for Prophylactic Treatment of Migraine and Tension Headaches in Adults: A Meta-analysis. Jama. 2012;307:1736-45. https://doi.org/10.1001/jama.2012.505.
Lambru G, Hill B, Murphy M, Tylova I, Andreou AP. A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain. 2020;21:61. https://doi.org/10.1186/s10194-020-01127-0.
Barbanti P, Aurilia C, Egeo G, Fofi L, Cevoli S, Colombo B, et al. Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study. Headache J Head Face Pain. 2021;61:363-72. https://doi.org/10.1111/head.14032.
Matteo E, Favoni V, Pascazio A, Pensato U, Benini M, Asioli GM, et al. Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna Headache Center. Neurol Sci. 2020;41:483-4. https://doi.org/10.1007/s10072-020-04667-0.
Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, et al. Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain. 2021;22:35. https://doi.org/10.1186/s10194-021-01247-1.
Ashina M, Amin FM, Kokturk P, Cohen JM, Konings M, Tassorelli C, et al. PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine. Pain Management. 2021;11:647-54. https://doi.org/10.2217/pmt-2021-0015.
Scheffler A, Schenk H, Wurthmann S, Nsaka M, Kleinschnitz C, Glas M, et al. CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience. J Headache Pain. 2021;22:111. https://doi.org/10.1186/s10194-021-01323-6.
Listed N authors. OnabotulinumtoxinA for Injection (Botox) For the Prophylaxis of Headaches in Adults With Chronic Migraine (> 15 Days per Month With Headache Lasting 4 Hours a Day or Longer) (Internet). CADTH Common Drug Reviews. 2015. Disponible en https://www.ncbi.nlm.nih.gov/books/NBK344307/
Altamura C, Cevoli S, Brunelli N, Aurilia C, Fofi L, Egeo G, et al. When should we consider chronic patients as non-responders to monoclonal antibodies targeting the CGRP pathway? J Neurol. 2021:1-3. https://doi.org/10.1007/s00415-021-10772-7.
Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020;94:10.1212/WNL.0000000000009169. https://doi.org/10.1212/wnl.0000000000009169.
Winner PK, Spierings ELH, Yeung PP, Aycardi E, Blankenbiller T, Grozinski-Wolff M, et al. Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine. Headache J Head Face Pain. 2019;59:1743-52. https://doi.org/10.1111/head.13654.
Dodick DW, Silberstein SD, Lipton RB, DeGryse RE, Adams AM, Diener H-C. Early onset of effect of onabotu-linumtoxinA for chronic migraine treatment: Analysis of PREEMPT data. Cephalalgia. 2018;39:945-56. https://doi.org/10.1177/0333102418825382.
Alpuente A, Gallardo VJ, Torres-Ferrus M, Alvarez-Sabin J, Pozo-Rosich P. Early efficacy and late gain in chronic and high-frequency episodic migraine with onabotulinumtoxinA. Eur J Neurol. 2019;26:1464-70. https://doi.org/10.1111/ene.14028.
Ahmed F, Gaul C, García-Moncó JC, Sommer K, Martelletti P, Investigators RP. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. J Headache Pain. 2019;20:26. https://doi.org/10.1186/s10194-019-0976-1.
Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Schneider G, Yedigarova L, et al. Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review. Pain Ther. 2021:1-18. https://doi.org/10.1007/s40122-021-00264-x.
Chen Y-Y, Ye X-Q, Tang T-C, She T-W, Chen M, Zheng H. Calcitonin Gene-Related Peptide Monoclonal Antibodies Versus Botulinum Neurotoxin a in the Preventive Treatment of Chronic Migraine: An Adjusted Indirect Treatment Comparison Meta-Analysis. Front Pharmacol. 2021;12:671845. https://doi.org/10.3389/fphar.2021.671845.
Toni T, Tamanaha R, Newman B, Liang Y, Lee J, Carrazana E, et al. Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxinA injections: case series. Neurol Sci. 2021:1-4. https://doi.org/10.1007/s10072-021-05547-x.
Silvestro M, Tessitore A, Clemente FS di, Battista G, Tedeschi G, Russo A. Additive Interaction Between Onabotulinum-toxin-A and Erenumab in Patients With Refractory Migraine. Front Neurol. 2021;12:656294. https://doi.org/10.3389/fneur.2021.656294.
Armanious M, Khalil N, Lu Y, Jimenez-Sanders R. Erenumab and OnabotulinumtoxinA Combination Therapy for the Prevention of Intractable Chronic Migraine without Aura: A Retrospective Analysis. J Pain Palliat Care Pharmacother. 2020;35:1-6 . https://doi.org/10.1080/15360288.2020.1829249
Alpuente A, Gallardo VJ, Caronna E, Torres-Ferrús M, Pozo-Rosich P. Partial and nonresponders to onabotulinumtoxinA can benefit from anti-CGRP monoclonal antibodies preventive treatment: A real-world evidence study. Eur J Neurol. 2021;28:2378-82. https://doi.org/10.1111/ene.14828.
Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38:1026-37. https://doi.org/10.1177/0333102418759786.
Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. New Engl J Med . 2017;377:2113-22. https://doi.org/10.1056/nejmoa1709038.
Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial. Jama Neurol. 2018;75:1080. https://doi.org/10.1001/jamaneurol.2018.1212.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.